Background. Children with cancer have an increased susceptibility to influenza infection. The objective of this study was to assess the immunogenicity of pandemic (H1N1) 2009 vaccine in children with cancer Methods. Children were recruited from the Royal Marsden Hospital, England, during November 2009. The vaccination schedule consisted of 2 doses of an AS03 B -adjuvanted vaccine given at days 0 and 21. Serological analysis was performed on blood samples obtained at day 0 and day 42. The primary immunological end point was the seroconversion rate, which was defined as the proportion of subjects with an individual 4-fold increase in hemagglutination inhibition titer and a postvaccination hemagglutination inhibition titer у1:32.
Children with cancer have an increased susceptibility to influenza infection [1] . They also have a higher mortality and morbidity rate from influenza, compared with healthy children [2, 3] . Impaired cell-mediated immunity leads to an increased risk of influenza, prolonged infection, and secondary bacterial infection. Retrospective reviews of influenza infection in children receiving treatment for cancer have reported an incidence of intensive care admissions secondary to influenza of 10%-15% and delays in chemotherapy in up to 40% of children [4, 5] . Current United Kingdom guidelines recommend annual influenza vaccination for all children receiving chemotherapy, up to 6 months after completion of chemotherapy and for all hematopoietic stem cell transplant recipients as long as they remain immunocompromised [6] . Several studies have examined the immunogenicity of influenza vaccines in children with cancer. However, with use of a primary immunological end point of seroconversion, defined as the proportion of subjects with an individual 4-fold increase in hemagglutination inhibition (HAI) titer after vaccination, 1 study reported that only 33%-52% of children with nonleukemic malignancies responded to each viral subunit in the trivalent inactivated influenza vaccine [7] . This study also showed that lymphopenia and intensity of chemotherapy regimen did not appear to influence seroconversion rates. Other studies involving children with acute lymphoblastic leukemia (ALL) receiving main- tenance therapy have shown that 40%-60% of recipients demonstrate a 4-fold increase in HAI titer after influenza vaccination [1, 8, 9] .
In March 2009, a novel swine-origin influenza A (H1N1) virus with molecular features of North American and Eurasian swine, avian, and human influenza virus was initially detected in Mexico and North America [10, 11] . The virus spread globally and was classified as a pandemic by the World Health Organization on 11 June 2009 [12] .
It was unclear how children with cancer who developed pandemic (H1N1) 2009 infection would behave. There was concern that immunocompromised children might require significant ventilator support, experience more serious bacterial secondary infection, or exhibit prolonged viral shedding. Furthermore, it was unknown how these children might respond to antivirals and the pandemic (H1N1) 2009 vaccine. Published studies describing the clinical course of H1N1 infection in children with cancer are sparse. One report of a nosocomial outbreak of H1N1 infection on a pediatric oncology ward described 3 of 8 patients who acquired secondary bacterial infections and 1 child who required intensive care and ventilation for 30 days [13] . Another report described mild H1N1 infections in 8 children receiving maintenance treatment for ALL, but 2 children receiving intensive ALL chemotherapy developed pneumonia, with 1 requiring intensive care [14] . Both studies involved unvaccinated children because this was prior to the availability of pandemic (H1N1) 2009 vaccine in these areas.
In the United Kingdom, the Department of Health recommended that patients who were in the current seasonal influenza vaccine at-risk groups should receive pandemic (H1N1) 2009 vaccine during the initial phase of its introduction. This group included children receiving chemotherapy or within 6 months of completion of chemotherapy and children after hematopoietic stem cell transplant who are considered to be immunosuppressed. The objective of this study was to assess the immunogenicity of pandemic (H1N1) 2009 vaccine in children with cancer and, therefore, to provide information to guide clinical management of individual patients.
METHODS

Study design.
Children who met Department of Health criteria to receive the pandemic (H1N1) 2009 vaccine as a priority were recruited from the Royal Marsden Hospital, England, during November 2009. Recruitment was conducted both by telephone and face to face among outpatients, clinics, and wards to maximize the number of eligible study participants over a short time period. Children were excluded if they had a previous history of laboratory-confirmed pandemic (H1N1) 2009 infection or a history of an anaphylactic reaction to any of the constituents or trace residues in the vaccine (egg and chicken protein, ovalbumin, formaldehyde, gentamicin sulphate, and sodium deoxycholate). Written informed consent was obtained from a parent or guardian. Because children were offered the vaccine as part of routine care, parents were not requested to complete diary cards, measure daily temperatures, or measure reaction sizes.
The vaccination schedule consisted of 2 doses of a splitvirion, AS03 B -adjuvanted vaccine given at days 0 and 21 ‫7ע(‬ days). The vaccine was administered intramuscularly into the deltoid muscle. Lymphocyte and neutrophil counts were recorded on day 0. Serological analysis was performed on blood samples taken at day 0 and day 42 (Ϫ7 to +14 days).
Vaccine details. The vaccine used in this study was Pan- Serum samples were treated with receptor-destroying enzyme (RDE; Denka Seiken), according to the manufacturer's protocol, and were processed in 2-fold serial dilutions starting at 1:8, with a final dilution of 1:16,384. Serum samples were tested in duplicate, and the geometric mean value was used for further statistical analysis. For the purposes of analysis, negative samples were assigned a titer of 1:4. Assays were performed in a blinded fashion at the Respiratory Virus Unit at the Centre for Infections, Health Protection Agency in London. The primary immunological end point was the seroconversion rate, which was defined as the proportion of subjects with an individual 4-fold increase in HAI titer after the second vaccine dose and a titer у1:32. The main secondary end points were differences in actual prevaccination geometric mean titers (GMT) and postvaccination GMT (seroconversion factor) and GMT fold increase between patient subgroups. An additional secondary end point was the proportion of patients who achieved a у3-fold increase in GMT after vaccination.
Statistical analysis. A formal sample size calculation was not performed because of the need to obtain estimates of vaccine immunogenicity and to complete the study as quickly as possible. Analysis was performed for all patients who had a second sample taken and were therefore evaluable for the primary end point, regardless of whether they received both vaccinations. A significance level of 5% and 95% confidence intervals were used for all analyses.
The relationship between a number of prognostic factors and the binary end points described above were assessed univariately with use of 2-sided Fisher's exact tests. Lymphocyte and neutrophil counts were also assessed as continuous variables by comparing counts between patients with or without seroresponse with use of a Mann-Whitney nonparametric test, because the data were skewed. Logistic regression was used to investigate the effect of prespecified prognostic factors of age, cancer type, treatment status, and lymphocyte count in combination on seroconversion rates. The Mann-Whitney test was used to assess differences in seroconversion factor and GMT fold increases between patient subgroups. All analyses was performed using the Stata 10 software package (StataCorp).
Ethical approval and compliance with guidelines. National United Kingdom Department of Health guidance was that all children who participated in this study were considered to be in a high-risk group for influenza infection and were therefore recommended to receive the pandemic (H1N1) 2009 vaccine as part of routine care. The clinical service to provide testing of immune responses to vaccination was offered to all such priority groups receiving the first batches of the pandemic (H1N1) 2009 vaccine. There was no allocation to intervention or control 
RESULTS
Fifty-seven children were recruited to this study. Three patients did not have a second sample obtained and are therefore not included in the analysis. Of the 54 remaining patients, 52 received both doses of vaccine and 2 patients received 1 vaccine dose but are included in this intention-to-treat analysis. Figure  1 shows details of study participants.
The analysis population of 54 children had a median age of 6.3 years (range, 1.4-16.6 years). The median time between the first and second vaccination was 21 days (range, 20-30 days), and the median time between administration of the second vaccine and obtaining of the second sample was 21 days (range, 13-52 days). One patient had obtainment of the second sample delayed beyond the time range originally stated because of a prolonged hospital admission but is included in the analysis.
Lymphocyte and neutrophil counts were available on day 0 for 51 children. The median lymphocyte count was lym- Table 1 .
Vaccine adverse events. One child with stage III B cell lymphoblastic lymphoma receiving maintenance treatment under Euro LB protocol developed methemoglobinemia 2 days after the first vaccine dose. This child had been receiving dapsone as Pneumocystis jiroveci pneumonia prophylaxis for several months before receiving the vaccine. Methemoglobinemia is a known complication of dapsone therapy [18] . It is unlikely that the AS03 B -adjuvanted pandemic (H1N1) 2009 vaccine was responsible, and no other cases of methemoglobinemia associated with this vaccine have been reported to the Medicines and Healthcare products Regulatory Agency [19] .
Parents verbally reported any vaccine-related events when attending for the second vaccine dose and subsequent blood test. Eleven (20.4%) of 54 children experienced local reactions after vaccination, including erythema (3 children), edema (4 children), and pain (7 children). Five (9.3%) of 54 children developed fever (temperature у38ЊC) within 48 h after vaccination, and all were admitted to the hospital. Four received intravenous antibiotics, and 2 of them were neutropenic at the time of hospital admission.
Seroconversion rate by HAI. Twenty-four (44.4%; 95% confidence interval [CI], 30.9%-58.6%) of 54 children demonstrated seroconversion with a 4-fold increase in HAI and a postvaccination HAI titer у1:32. Four children (7.4%) had prevaccination HAI titers у1:32; of these, 3 achieved a 4-fold increase in HAI titer after vaccination. Three patients (5.6%) had a 4-fold increase in HAI titer but did not achieve a postvaccinination HAI titer у1:32. Table 2 shows seroconversion rates determined by HAI titer for different cancer subgroups. The largest subgroup in this study involved children with ALL, who demonstrated a seroconversion rate of 33.3% (95% CI, 16.5%-54.0%; 9 of 27 children). Fourteen children were receiving ALL maintenance therapy at the time of vaccination, and 4 (28.6%; 95% CI, 1.5%-55.6%) of 14 achieved seroconversion. Furthermore, seroconversion was achieved in 3 (23.1%; 95% CI, 5.0%-71.1%) of 13 children with ALL who were receiving dexamethasone at the time of vaccination, compared with 6 (42.9%; 95% CI, 17.7%-53.8%;
) of 14 who P p .42 were not receiving dexamethasone. Table 3 shows univariate comparisons of seroconversion rates between different patient subgroups. Because of small patient numbers, some subgroups were combined into larger groups for the purposes of univariate and multivariate analysis.
All univariate seroconversion analyses were also repeated after excluding patients who received only 1 vaccination (n p ) and those who were hematopoietic stem cell transplant re-2 cipients ( ). The seroconversion rate of the remaining 48 n p 4 patients was 45.8% (95% CI, 31.4%-60.8%; 22 of 48 patients). These results are shown in the Appendix. Prespecified prognostic factors of age, receiving or not receiving treatment at the time of first vaccination, cancer type, and lymphopenia were analyzed in a multivariate model shown in Table 4 .
Pre-and postvaccination GMTs and fold increases. Table 5 shows the geometric mean and associated 95% CIs of prevaccination GMT, postvaccination GMT, and fold increases between different patient subgroups. The prevaccination GMT varies significantly with cancer type, lymphocyte count, and treatment status. Children with solid tumors and those not receiving treatment had higher prevaccination GMTs. Despite the fact that prevaccination GMTs were higher among those who were not lymphopenic, lymphocyte count was not shown be a significant predictor of seroconversion in both univariate and multivariable analysis. The proportion of patients who achieved a у3-fold increase in GMT after vaccination is shown in the Appendix.
DISCUSSION
This study of children with cancer in the United Kingdom demonstrates a limited but acceptable response to a pandemic (H1N1) 2009 vaccine. The opportunistic and time-limited recruitment of children to this study resulted in a heterogeneous group of patients with varying diagnoses and degrees of immunosuppression. It was therefore difficult to stratify participants according to intensity of treatment and to correlate this with seroconversion rates. The seroconversion rate was not af- , by univariate analysis). Similarly, there were P p .03 significant differences in pre-and postvaccination GMTs among children who had solid tumors, compared with those with hematological malignancies.
It is important to note that definitions of serological response and protective titers have been derived from healthy immunocompetent children, and therefore, the relevance to immunocompromised children is unknown. Hence, 3-fold increases in HAI were also calculated for these patients. An extra 6 patients achieved seroresponse by this definition (30 [55.6%; 95% CI, 41.4%-69.1%] of 54 children), compared with 24 (44.4%; 95% CI, 30.9%-58.6%) of 54 children when using a definition based on a 4-fold increase.
The seroconversion rate among children with ALL was lower than expected on the basis of published studies of influenza vaccination in this patient group [1, 8, 9] . This is the first published study of any vaccine in children receiving chemotherapy per the United Kingdom Medical Research Council United Kingdom ALL 2003 protocol. This protocol has been built on the foundation of previous ALL trials in the United Kingdom, with the adoption of pegylated asparaginase throughout the induction and intensification phases. Over the years, the intensity of chemotherapy for ALL has increased, as have the survival rates [20] . Published influenza vaccine studies, which have generally demonstrated higher seroconversion rates, have been more selective regarding patients for inclusion, including children who were receiving less intensive treatment and were therefore less immunosuppressed. This pragmatic study did not exclude children who were receiving steroids at the time of vaccination nor did it exclude those who were inpatients and, therefore, likely to be more unwell.
Univariate ) as more likely to experience P p .02 seroconversion. The effect of having completed treatment at the time of vaccination in the multivariable model remained significant (odds ratio, 12.0; 95% CI, 0.99-145.97; ) P p .05 after adjusting for age, cancer type, and lymphopenia. However, these findings may also be the result of the significantly higher prevaccination GMT, shown in Table 5 . It should be noted that the CIs are wide and the sample size is small. However, it is well established that children who have completed treatment show responses to influenza vaccine more comparable with healthy controls [1, 21, 22] .
Despite the fact that children aged !10 years received 0.25 mL of vaccine, compared with 0.5 mL of vaccine administered to those aged у10 years, there was no evidence of a relationship between age and seroresponse rates according to HAI titer or GMT.
When grouped categorically, lymphopenia and neutropenia did not appear to correlate with seroconversion in univariate and multivariate analysis, although prevaccination GMTs were higher among those children who were not lymphopenic. When neutrophil and lymphocyte count were considered as continuous variables against seroconversion rates, the median neutrophil count was higher among those who experienced seroconversion than among those who did not. It also appeared that there may be a difference in the distribution of neutrophil counts between those who experienced seroconversion and those who did not ( , by Mann-Whitney test), but the P p .03 clinical significance of this result is uncertain (Appendix).
This is the first study of responses to an adjuvanted vaccine in children with cancer. An adjuvant is known to increase the immunogenicity of a vaccine, and it has been shown that adjuvanted influenza vaccines induce greater and broader immune responses in healthy children [23] . A study of pandemic (H1N1) 2009 vaccines in healthy children in the United Kingdom reported that 98.7% of children demonstrated seroconversion with the adjuvanted vaccine, whereas only 44% of children in this study demonstrated seroconversion with the same vaccine [24] . Adjuvants, such as aluminium hydroxide and MF59, appear to induce the secretion of cytokines that increase the recruitment of immune cells into the injection site and accelerate monocyte differentiation into dendritic cells [25] . However, the mechanism by which AS03 B enhances immunogenicity is unknown, and it is uncertain whether immunocompromised children respond to this adjuvant in the same way as healthy children. Further studies are warranted to compare responses to nonadjuvanted pandemic (H1N1) 2009 vaccines in this patient cohort and also to assess antibody persistence for the next influenza season.
This first study of the immunogenicity of an AS03 B -adjuvanted pandemic (H1N1) 2009 vaccine in children with cancer showed impaired but useful seroconversion rates. A higher proportion of children with solid tumors demonstrated seroconversion, compared with those with hematological diagnoses. Children who had completed treatment had higher seroconversion rates than those who were receiving treatment. Age, lymphocyte count, and neutrophil count did not adversely affect seroconversion rates in this patient cohort. This study supports yearly vaccination to protect individuals who are at greatest risk of influenza and its comorbidities because of their immunosuppressed status.
APPENDIX SUPPLEMENTARY DATA
All univariate seroresponse analyses were repeated with patients who only received 1 vaccination ( ) and those who were n p 2 hematopoietic stem cell transplant recipients ( ) excluded. n p 4 Of the remaining 48 patients, 22 (45.8%) experienced seroresponse. Table A1 shows univariate comparisons of the proportions with seroresponse between different patient subgroups.
Lymphocyte and neutrophil count were also considered to be continuous variables, with differences in counts between those who experienced seroresponse and those who did not assessed using the Mann-Whitney nonparametric test. Results are shown in Table A2 . Thirty of 54 patients had a у3-fold increase in GMT, 55.6% (95% CI, 41.4%-69.1%) of the entire cohort. Table A3 compares proportions achieving a 3-fold increase in GMT between different patient subgroups. 
